Seguir
Timothy Daly
Timothy Daly
Sorbonne Université
Dirección de correo verificada de sorbonne-universite.fr - Página principal
Título
Citado por
Citado por
Año
Identifying health conditions associated with Alzheimer's disease up to 15 years before diagnosis: an agnostic study of French and British health records
T Nedelec, B Couvy-Duchesne, F Monnet, T Daly, M Ansart, L Gantzer, ...
The Lancet Digital Health 4 (3), e169-e178, 2022
392022
The ethics of innovation for Alzheimer’s disease: the risk of overstating evidence for metabolic enhancement protocols
T Daly, I Mastroleo, D Gorski, S Epelbaum
Theoretical Medicine and Bioethics 41 (5), 223-237, 2020
202020
fMRI neurofeedback of higher visual areas and perceptual biases
I Habes, S Rushton, SJ Johnston, MO Sokunbi, K Barawi, M Brosnan, ...
Neuropsychologia 85, 208-215, 2016
202016
Contribution of glycogen in supporting axon conduction in the peripheral and central nervous systems: the role of lactate
TW Chambers, TP Daly, A Hockley, AM Brown
Frontiers in neuroscience 8, 120249, 2014
172014
Amyloid-β in Alzheimer’s disease: A study of citation practices of the amyloid cascade hypothesis between 1992 and 2019
T Daly, M Houot, A Barberousse, Y Agid, S Epelbaum
Journal of Alzheimer's Disease 74 (4), 1309-1317, 2020
162020
A proposal to make biomedical research into Alzheimer’s disease more democratic following an international survey with researchers
T Daly, M Houot, A Barberousse, A Petit, S Epelbaum
Journal of Alzheimer's Disease Reports 5 (1), 637-645, 2021
152021
Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration
AJ Espay, K Herrup, T Daly
Handbook of Clinical Neurology 192, 143-154, 2023
122023
Avoiding over-reliance on multi-domain interventions for dementia prevention
T Daly, I Mastroleo, R Migliaccio
Journal of Alzheimer's Disease 90 (3), 989-992, 2022
122022
An ethical argument for ending human trials of amyloid-lowering therapies in Alzheimer’s disease
T Daly, K Herrup, AJ Espay
AJOB neuroscience 15 (2), 80-81, 2024
102024
An argument for simple tests of treatment of Alzheimer’s disease
T Daly, I Mastroleo, V Henry, M Bourdenx
Journal of Alzheimer's Disease 86 (1), 49-52, 2022
102022
The letter as a forum to embed ethics into the scientific literature
T Daly
Accountability in Research, 1-2, 2023
92023
Giving a fairer face to urban space: Progress on the long road to dementia prevention
T Daly
International Journal of Geriatric Psychiatry, 2021
92021
Dementia prevention guidelines should explicitly mention deprivation
T Daly
AJOB neuroscience 15 (1), 73-76, 2024
72024
Lecanemab: turning point, or status quo? An ethics perspective
T Daly
Brain 146 (9), e71-e72, 2023
72023
From association to intervention: the Alzheimer’s Disease-Associated Processes and Targets (ADAPT) ontology
T Daly, V Henry, M Bourdenx
Journal of Alzheimer's Disease 94 (s1), S87-S96, 2023
72023
Need for truthfulness in dementia research
TP Daly
bmj 380, 2023
62023
The accelerated Approval of Aducanumab Invites a Rethink of the Current Model of Drug Development for Alzheimer's Disease
T Daly, S Epelbaum
AJOB Neuroscience, 2022
62022
Learning from the amyloid hypothesis: Adaptability, brevity, and clarity of ideas
T Daly
Neurological Sciences 44 (6), 2177-2178, 2023
52023
From lifestyle to stimulation for dementia prevention in Brazil
T Daly
The Lancet Regional Health–Americas 11, 2022
52022
Avoiding exceptionalism and silver bullets: Lessons from public health ethics and Alzheimer’s disease
I Mastroleo, T Daly
The American Journal of Bioethics 21 (12), 25-28, 2021
52021
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20